For CROs & Sponsors
Ryght is a secure, enterprise-grade GenAI platform equipped with an expanding arsenal of copilots designed to accelerate each stage of the clinical trial workflow. Ryght helps you connect with and collaborate with research sites more efficiently.
For Research Sites
All copilots and applications on Ryght are always free for research sites. Ryght offers a suite of AI-powered copilots designed to empower research sites with greater efficiency and improve your collaboration with CROs and sponsors.
For AI
Builders
Empower your team with AI superpowers: Unleash the potential of custom copilots and tackle vast structured or unstructured datasets effortlessly on Ryght's API-driven platform. We help you transform your workflows with precision and speed.
"We've always been excited by the potential of AI to revolutionise clinical trial payment workflows, but data security and privacy concerns have been a significant roadblock.
Our partnership with Ryght clears the way for us to innovate on solutions like intelligent data validation, which will dramatically boost the accuracy, efficiency, and speed of our payment processes while saving valuable time and effort for sponsors, sites and participants."
Jon Anderson
CEO
nmible
"Ryght's cutting-edge technology aligns perfectly with our vision of using the power and potential of AI to transform healthcare data into novel, actionable insights that help clinicians practice more proactive care that delivers better patient outcomes."
Sean Cassidy
CEO
Lucem Health
"We are thrilled to collaborate with Ryght and utilize their GenAI platform to advance our clinical trial processes. Ryght's innovative technology complements our dedication to innovation and excellence seamlessly. Through the application of AI, we aim to further support our biotech clients to develop transformative therapeutics in areas of unmet need.”
Yvonne Lungershausen
CEO
Avance Clinical
"Ryght's cutting-edge technology aligns perfectly with our commitment to innovation that enables our customers to rapidly identify clinically qualified patients, leading to faster enrollment in clinical trials.
By harnessing the power of AI, we can continue to unlock new insights and accelerate access to clinical research."
Dave Levin
CEO
BEKhealth
Our NIMBC clinical research program greatly benefited from the Ryght platform. As a clinical researcher, I heavily relied on the platform’s literature review applications to delve into cytokine ratios and cytokine diagnostics used in patient treatment. Our scientific team had previously explored this, but not to the extent that the Ryght tool was able to in a brief time. Through Ryght, we could access comprehensive information and gain new perspectives into areas the Ryght tool had newly identified. This is like having a graduate student or research resource dedicated to our project. The Ryght tool identified some cytokine relationships we had not explored and provided a rapid summary with documented literature sources. This saved us valuable time and resources and expanded our knowledge in understanding our PD results. Thanks to Ryght, we were empowered to advance our research efficiently and effectively.
Shane Roberts
Sr. Clinical Research Associate
Surge Therapeutics
"At the University of Adelaide, we are committed to advancing world-class research that addresses many of the challenges faced by society. Our new partnership with Ryght and their cutting-edge AI technology is a testament to this commitment. By working together, we can leverage our collective expertise to develop innovative, responsible and tested solutions for better public health and other critical issues and bring Australia’s AI capabilities up to world-class standards where they belong.”
Professor Mark Hutchinson BSc, PhD
Interim Director of the Institute for Photonics and Advanced Sensing (IPAS)
Adelaide University
